Analysis of clinical patient-specific pre-treatment quality assurance with the new helical tomotherapy platform, following the AAPM TG-218 report

Abstract Purpose This study presents patient-specific quality assurance (QA) results from the first 395 clinical cases for the new helical TomoTherapy® platform (Radixact) coupled with dedicated Precision TPS. Methods The passing rate of the Gamma Index (GP%) of 395 helical QA of patient-specific to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marco Fusella, Samuele Cavinato, Alessandra Germani, Marta Paiusco, Nicola Pivato, Marco Andrea Rossato, Anthony Scott, Alessandro Scaggion
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	TomoTherapy Quality assurance Pre-treatment quality assurance IMRT QA Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/20894cc3777748a5baee70b4f93c0a5a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:20894cc3777748a5baee70b4f93c0a5a
record_format	dspace
spelling	oai:doaj.org-article:20894cc3777748a5baee70b4f93c0a5a2021-11-28T12:13:58ZAnalysis of clinical patient-specific pre-treatment quality assurance with the new helical tomotherapy platform, following the AAPM TG-218 report10.1186/s13014-021-01952-w1748-717Xhttps://doaj.org/article/20894cc3777748a5baee70b4f93c0a5a2021-11-01T00:00:00Zhttps://doi.org/10.1186/s13014-021-01952-whttps://doaj.org/toc/1748-717XAbstract Purpose This study presents patient-specific quality assurance (QA) results from the first 395 clinical cases for the new helical TomoTherapy® platform (Radixact) coupled with dedicated Precision TPS. Methods The passing rate of the Gamma Index (GP%) of 395 helical QA of patient-specific tomotherapy, acquired with ArcCHECK, is presented, analysed and correlated to various parameters of the plan. Following TG-218 recommendations, the clinic specific action limit (ALcs) and tolerance limit (TLcs) were calculated for our clinic and monitored during the analysed period. Results The mean values (± 1 standard deviation) of GP% (3%/2 mm) (both global and local normalization) are: 97.6% and 90.9%, respectively. The proposed ALcs and TLcs, after a period of two years’ process monitoring are 89.4% and 91.1% respectively. Conclusions The phantom measurements closely match the planned dose distributions, demonstrating that the calculation accuracy of the new Precision TPS and the delivery accuracy of the Radixact unit are adequate, with respect to international guidelines and reports. Furthermore, a first correlation with the planning parameters was made. Action and tolerance limits have been set for the new Radixact Linac.Marco FusellaSamuele CavinatoAlessandra GermaniMarta PaiuscoNicola PivatoMarco Andrea RossatoAnthony ScottAlessandro ScaggionBMCarticleTomoTherapyQuality assurancePre-treatment quality assuranceIMRT QAMedical physics. Medical radiology. Nuclear medicineR895-920Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENRadiation Oncology, Vol 16, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	TomoTherapy Quality assurance Pre-treatment quality assurance IMRT QA Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	TomoTherapy Quality assurance Pre-treatment quality assurance IMRT QA Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Marco Fusella Samuele Cavinato Alessandra Germani Marta Paiusco Nicola Pivato Marco Andrea Rossato Anthony Scott Alessandro Scaggion Analysis of clinical patient-specific pre-treatment quality assurance with the new helical tomotherapy platform, following the AAPM TG-218 report
description	Abstract Purpose This study presents patient-specific quality assurance (QA) results from the first 395 clinical cases for the new helical TomoTherapy® platform (Radixact) coupled with dedicated Precision TPS. Methods The passing rate of the Gamma Index (GP%) of 395 helical QA of patient-specific tomotherapy, acquired with ArcCHECK, is presented, analysed and correlated to various parameters of the plan. Following TG-218 recommendations, the clinic specific action limit (ALcs) and tolerance limit (TLcs) were calculated for our clinic and monitored during the analysed period. Results The mean values (± 1 standard deviation) of GP% (3%/2 mm) (both global and local normalization) are: 97.6% and 90.9%, respectively. The proposed ALcs and TLcs, after a period of two years’ process monitoring are 89.4% and 91.1% respectively. Conclusions The phantom measurements closely match the planned dose distributions, demonstrating that the calculation accuracy of the new Precision TPS and the delivery accuracy of the Radixact unit are adequate, with respect to international guidelines and reports. Furthermore, a first correlation with the planning parameters was made. Action and tolerance limits have been set for the new Radixact Linac.
format	article
author	Marco Fusella Samuele Cavinato Alessandra Germani Marta Paiusco Nicola Pivato Marco Andrea Rossato Anthony Scott Alessandro Scaggion
author_facet	Marco Fusella Samuele Cavinato Alessandra Germani Marta Paiusco Nicola Pivato Marco Andrea Rossato Anthony Scott Alessandro Scaggion
author_sort	Marco Fusella
title	Analysis of clinical patient-specific pre-treatment quality assurance with the new helical tomotherapy platform, following the AAPM TG-218 report
title_short	Analysis of clinical patient-specific pre-treatment quality assurance with the new helical tomotherapy platform, following the AAPM TG-218 report
title_full	Analysis of clinical patient-specific pre-treatment quality assurance with the new helical tomotherapy platform, following the AAPM TG-218 report
title_fullStr	Analysis of clinical patient-specific pre-treatment quality assurance with the new helical tomotherapy platform, following the AAPM TG-218 report
title_full_unstemmed	Analysis of clinical patient-specific pre-treatment quality assurance with the new helical tomotherapy platform, following the AAPM TG-218 report
title_sort	analysis of clinical patient-specific pre-treatment quality assurance with the new helical tomotherapy platform, following the aapm tg-218 report
publisher	BMC
publishDate	2021
url	https://doaj.org/article/20894cc3777748a5baee70b4f93c0a5a
work_keys_str_mv	AT marcofusella analysisofclinicalpatientspecificpretreatmentqualityassurancewiththenewhelicaltomotherapyplatformfollowingtheaapmtg218report AT samuelecavinato analysisofclinicalpatientspecificpretreatmentqualityassurancewiththenewhelicaltomotherapyplatformfollowingtheaapmtg218report AT alessandragermani analysisofclinicalpatientspecificpretreatmentqualityassurancewiththenewhelicaltomotherapyplatformfollowingtheaapmtg218report AT martapaiusco analysisofclinicalpatientspecificpretreatmentqualityassurancewiththenewhelicaltomotherapyplatformfollowingtheaapmtg218report AT nicolapivato analysisofclinicalpatientspecificpretreatmentqualityassurancewiththenewhelicaltomotherapyplatformfollowingtheaapmtg218report AT marcoandrearossato analysisofclinicalpatientspecificpretreatmentqualityassurancewiththenewhelicaltomotherapyplatformfollowingtheaapmtg218report AT anthonyscott analysisofclinicalpatientspecificpretreatmentqualityassurancewiththenewhelicaltomotherapyplatformfollowingtheaapmtg218report AT alessandroscaggion analysisofclinicalpatientspecificpretreatmentqualityassurancewiththenewhelicaltomotherapyplatformfollowingtheaapmtg218report
_version_	1718408125602594816

Analysis of clinical patient-specific pre-treatment quality assurance with the new helical tomotherapy platform, following the AAPM TG-218 report

Ejemplares similares